PF 755616Alternative Names: PF-755616
Latest Information Update: 03 Oct 2008
At a glance
- Originator Pfizer
- Class Antirheumatics
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Rheumatoid arthritis
Most Recent Events
- 03 Oct 2008 Discontinued - Phase-I for Rheumatoid arthritis in USA (unspecified route)
- 20 Dec 2006 Phase-I clinical trials in Rheumatoid arthritis in USA (unspecified route)